Acrivon Therapeutics, Common Stock Analysis
| ACRV Stock | 7.52 0.17 2.31% |
Acrivon Therapeutics, Common is undervalued with Real Value of 11.1 and Target Price of 23.13. The main objective of Acrivon Therapeutics, stock analysis is to determine its intrinsic value, which is an estimate of what Acrivon Therapeutics, Common is worth, separate from its market price. There are two main types of Acrivon Therapeutics,'s stock analysis: fundamental analysis and technical analysis.
The Acrivon Therapeutics, stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Acrivon Therapeutics, is usually not traded on Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day. Acrivon Stock trading window is adjusted to America/New York timezone.
Acrivon |
Acrivon Stock Analysis Notes
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.19. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acrivon Therapeutics, recorded a loss per share of 2.66. The entity had not issued any dividends in recent years. For more info on Acrivon Therapeutics, Common please contact the company at 617 207 8979 or go to https://www.acrivon.com.Acrivon Therapeutics, Investment Alerts
| Acrivon Therapeutics, generated a negative expected return over the last 90 days | |
| Acrivon Therapeutics, has high historical volatility and very poor performance | |
| Net Loss for the year was (60.39 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Acrivon Therapeutics, generates negative cash flow from operations | |
| Acrivon Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 76.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 19910 shares by Blume-jensen Peter of Acrivon Therapeutics, at 6.44 subject to Rule 16b-3 |
Acrivon Therapeutics, Upcoming and Recent Events
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Acrivon Largest EPS Surprises
Earnings surprises can significantly impact Acrivon Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-05-14 | 2024-03-31 | -0.84 | -0.73 | 0.11 | 13 | ||
2024-03-28 | 2023-12-31 | -0.73 | -0.86 | -0.13 | 17 | ||
2023-03-28 | 2022-12-31 | -1.09 | -0.8 | 0.29 | 26 |
Acrivon Therapeutics, Environmental, Social, and Governance (ESG) Scores
Acrivon Therapeutics,'s ESG score is a quantitative measure that evaluates Acrivon Therapeutics,'s performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Acrivon Therapeutics,'s operations that may have significant financial implications and affect Acrivon Therapeutics,'s stock price as well as guide investors towards more socially responsible investments.
Acrivon Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dafna Capital Management Llc | 2024-09-30 | 112.4 K | Northern Trust Corp | 2024-09-30 | 105.4 K | Ubs O'connor Llc | 79.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 77 K | Baker Bros Advisors Lp | 2024-09-30 | 52.9 K | Renaissance Technologies Corp | 2024-09-30 | 45.9 K | Exchange Traded Concepts, Llc | 2024-06-30 | 42.9 K | Springbok Capital Management, Llc | 2024-09-30 | 37.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 36.6 K | Ra Capital Management, Llc | 2024-09-30 | 8.3 M | Perceptive Advisors Llc | 2024-09-30 | 5.4 M |
Acrivon Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 234.14 M.Acrivon Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.54) | (0.56) | |
| Return On Assets | (0.44) | (0.46) | |
| Return On Equity | (0.50) | (0.47) |
Management Efficiency
Acrivon Therapeutics, has return on total asset (ROA) of (0.2441) % which means that it has lost $0.2441 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3778) %, meaning that it created substantial loss on money invested by shareholders. Acrivon Therapeutics,'s management efficiency ratios could be used to measure how well Acrivon Therapeutics, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2024. Return On Capital Employed is likely to drop to -0.56 in 2024. Net Tangible Assets is likely to climb to about 205.8 M in 2024, whereas Total Assets are likely to drop slightly above 117.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.49 | 5.76 | |
| Tangible Book Value Per Share | 5.49 | 5.76 | |
| Enterprise Value Over EBITDA | (1.29) | (1.36) | |
| Price Book Value Ratio | 0.90 | 0.94 | |
| Enterprise Value Multiple | (1.29) | (1.36) | |
| Price Fair Value | 0.90 | 0.94 | |
| Enterprise Value | 77.3 M | 73.4 M |
The strategic initiatives led by Acrivon Therapeutics,'s management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Assets (0.24) | Return On Equity (0.38) |
Technical Drivers
As of the 28th of November, Acrivon Therapeutics, shows the Risk Adjusted Performance of (0.03), mean deviation of 2.87, and Standard Deviation of 4.21. Acrivon Therapeutics, technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Acrivon Therapeutics, information ratio and kurtosis to decide if Acrivon Therapeutics, is priced correctly, providing market reflects its regular price of 7.52 per share. Given that Acrivon Therapeutics, has information ratio of (0.08), we suggest you to validate Acrivon Therapeutics, Common's prevailing market performance to make sure the company can sustain itself at a future point.Acrivon Therapeutics, Price Movement Analysis
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Acrivon Therapeutics, middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Acrivon Therapeutics,. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Acrivon Therapeutics, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acrivon Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acrivon Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acrivon Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Acrivon Therapeutics, Outstanding Bonds
Acrivon Therapeutics, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Acrivon Therapeutics, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Acrivon bonds can be classified according to their maturity, which is the date when Acrivon Therapeutics, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| ACRISURE FINANCE INC Corp BondUS00489LAF04 | View | |
| Acrisure LLC 144A Corp BondUS00489LAH69 | View |
Acrivon Therapeutics, Predictive Daily Indicators
Acrivon Therapeutics, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Acrivon Therapeutics, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Acrivon Therapeutics, Corporate Filings
F4 | 27th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 25th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 21st of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 11th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 3rd of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 16th of September 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Acrivon Therapeutics, Forecast Models
Acrivon Therapeutics,'s time-series forecasting models are one of many Acrivon Therapeutics,'s stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acrivon Therapeutics,'s historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Acrivon Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Acrivon Therapeutics, prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acrivon shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Acrivon Therapeutics,. By using and applying Acrivon Stock analysis, traders can create a robust methodology for identifying Acrivon entry and exit points for their positions.
| Last Reported | Projected for Next Year |
Current Acrivon Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acrivon analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acrivon analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 23.13 | Strong Buy | 10 | Odds |
Most Acrivon analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acrivon stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acrivon Therapeutics,, talking to its executives and customers, or listening to Acrivon conference calls.
Acrivon Stock Analysis Indicators
Acrivon Therapeutics, Common stock analysis indicators help investors evaluate how Acrivon Therapeutics, stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acrivon Therapeutics, shares will generate the highest return on investment. By understating and applying Acrivon Therapeutics, stock analysis, traders can identify Acrivon Therapeutics, position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 29.9 M | |
| Common Stock Shares Outstanding | 22.1 M | |
| Total Stockholder Equity | 121.2 M | |
| Property Plant And Equipment Net | 7.9 M | |
| Cash And Short Term Investments | 127.5 M | |
| Cash | 36 M | |
| Accounts Payable | 5 M | |
| Net Debt | -31.4 M | |
| 50 Day M A | 7.514 | |
| Total Current Liabilities | 13.3 M | |
| Other Operating Expenses | 67.2 M | |
| Non Current Assets Total | 8.6 M | |
| Non Currrent Assets Other | 251 K | |
| Stock Based Compensation | 11.6 M |
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.